MedTrace Logo

Asia Study Group of Prostate Cancer (A-CaP Study)

NCT02873013 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2019-08-07

No results posted yet for this study

Summary

This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.

Conditions

Sponsors & Collaborators

  • Japan Study Group of Prostate Cancer

    lead OTHER

Principal Investigators

  • Hideyuki Akaza, M.D., Ph.D. · J-CaP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-03-31
Completion
2026-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873013 on ClinicalTrials.gov